ANRO

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on redefining psychiatry by leveraging neurobiology to develop personalized and effective treatment options. The Company's Precision Psychiatry Platform measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to identify which patients are likely to respond to its product candidates. Its clinical-stage pipeline includes drug candidates in bipolar depression, major depressive disorder, treatment resistant depression (TRD), and schizophrenia, and other mental health conditions. Its product candidates include ALTO-100, ALTO-300, ALTO-207, ALTO-203, ALTO-101, ALTO-202, and ALTO-208. ALTO-100 is a first-in-class, oral small molecule believed to work through enhancing neural plasticity in the hippocampus, a brain region important for both cognition and mood. ALTO-203 is an oral small molecule histamine H3 receptor inverse agonist.

Wall Street analysts forecast ANRO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANRO is 30.71 USD with a low forecast of 15.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Alto Neuroscience Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Alto Neuroscience Inc. EPS for the last quarter amounts to -0.52 USD, decreased -16.13 % YoY.

Alto Neuroscience Inc (ANRO) has 76 emplpoyees as of December 16 2025.

Today ANRO has the market capitalization of 530.61M USD.